Good news! Domestic anti-cancer drugs for hospitals and more than 350 pharmacies nationwide

Pharmaceutical Network Industry Dynamic) Baiji Shenzhou announced on June 15 thin that the company's independent research and development of a new generation of BTK inhibitor Bai Yueze (generic name: Zebutini capsules) began to face hospitals and pharmacies throughout the country to supply medicineIt is reported that the first batch of drugs will quickly cover more than 350 pharmacies across the country, at the same time will be in hospitals around the start of supplythe first prescription is currently issued in a hospital affiliated with Suzhou University, which also means that the first FDA approval in the United States listed in the local research and development of new anti-cancer drugs, the first domestic domestic BTK inhibitors listed in the country to achieve commercial supply, will be the good news for domestic lymphoma patientslymphoma is a group of malignant tumors originating in the lymphoma system, one of the top ten malignant tumors in ChinaAccording to the data, BTK is currently a prominent front-line target in blood cancer research, with Frost and Sullivan previously predicting that the BTK drug market will reach $17.8 billion by 2030 as penetration increases and indications expandIs a new type of powerful inhibitor targeted at BTK, primarily for the treatment of adult cell lymphoma (MCL) and adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma patients who have previously received at least one treatmentCompared with a generation of BTK inhibitors, with better target selectivity and safety through molecular structure optimization, and a long-lasting BTK inhibition effect, the effect is goodJune 3, 2020, MsBai was approved for the treatment of adult patients with at least one treatment, adult chronic lymphocytic lymphoma (CLL)/small lymphoma (SLL) patients who have previously received at least one treatmentit is understood that after the approval in China, Baiji Shenzhou Suzhou Industrialization Base is responsible for commercial production, the base was completed in November 2017, mainly responsible for the clinical and commercial production of small molecule drugsAt present, the base's preparation production capacity of up to 100 million capsules per year, at the same time can be based on actual needs for flexible scheduling, to meet the needs of patientsJune 12, at the 25th Annual Meeting of the European Society of Hematology (EHA), Baiji Shenzhou announced data on BTK inhibitor Bacudinx (Zebtinib) for the treatment of recurrent lymphoma (MZL) and other B-cell malignancies in the pertinated rim (R/R) and anti-PD-1 antibody Bezean (Terellisia) for the treatment of R/R/T lymphomaZebutini demonstrated effectiveness and safety in a number of indications, including R/R MZL, it was notedA potentially registered Phase 2 clinical trial for the treatment of R/R MZL patients is currently completedit is understood that Baiji Shenzhou is actively promoting the commercialization process of Bai Yueze In addition to being approved in China and the United States, The application for new drug listing in Israel has been accepted In Asia, Bai Yueze has recently been granted the "orphan medicine" status by the Korea Food and Drug Administration, in addition, Baiji Shenzhou also plans to the European Drug Administration this year to submit the application for the listing of budge zeaze new drug in the first quarter of 2020, the company's unaudited financial data showed zebuttini's product revenue in the U.S of $720,000 For zebutini domestic listing of the company's impact, the company's relevant person in charge said that the drug market potential is very large, the specific figures can not be disclosed at this time, but the product is certainly one of the company's main products "There will certainly be more people-friendly in terms of price, and we want to push for the drug to be included in the national health insurance as soon as possible." "